In our previous post, we outlined the dangers of Cytokine Release Syndrome (CRS) and the importance of preclinical Cytokine Release Assays (CRAs) when developing monoclonal antibodies (mAbs) that interact with the patient’s immune system. In this second post, we describe the different kinds of assays in use and how these …
![](https://ddblog.labcorp.com/wp-content/uploads/2019/10/data-image-samlois-1024x684.jpg)